XtalPi Holdings Ltd

HKSE 2228.HK

XtalPi Holdings Ltd Net Cash Used For Investing Activities for the year ending December 31, 2023: USD 103.61 M

XtalPi Holdings Ltd Net Cash Used For Investing Activities is USD 103.61 M for the year ending December 31, 2023, a 125.93% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • XtalPi Holdings Ltd Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -399.63 M, a -3,503.54% change year over year.
  • XtalPi Holdings Ltd Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -11.09 M.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
SV Wall Street
HKSE: 2228.HK

XtalPi Holdings Ltd

CEO Dr. Jian Ma Ph.D.
IPO Date June 21, 2010
Location China
Headquarters The third floor of the second phase of the International Biomedical Industrial Park, No. 2 Hongliu Road, Futian District
Employees 760
Sector Health Care
Industries
Pharmaceuticals Biotechnology Chemicals & Advanced Materials
Description

XtalPi Holdings Limited, an investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. The company's drug discovery solutions cover the whole drug discovery and research process, including target validation, hit identification, lead generation, lead optimization, and PCC nomination covering various modalities, which comprise small molecules, antibodies, peptides, ADC, and PROTAC. Its intelligent automation solutions focus on AI- and automation-enabled novel drug and materials discovery and research. The company was formerly known as QuantumPharm Inc. and changed its name to XtalPi Holdings Limited in December 2024. XtalPi Holdings Limited was founded in 2015 and is headquartered in Shenzhen, China.

StockViz Staff

February 5, 2025

Any question? Send us an email